Viking Therapeutics Inc (NASDAQ: VKTX) kicked off on Friday, down -1.08% from the previous trading day, before settling in for the closing price of $27.85. Over the past 52 weeks, VKTX has traded in a range of $18.92-$81.81.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded -86.48%. With a float of $108.99 million, this company’s outstanding shares have now reached $112.29 million.
Let’s determine the extent of company efficiency that accounts for 36 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Viking Therapeutics Inc (VKTX) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Viking Therapeutics Inc is 2.96%, while institutional ownership is 72.55%. The most recent insider transaction that took place on Mar 31 ’25, was worth 29,943. In this transaction Director of this company bought 1,240 shares at a rate of $24.15, taking the stock ownership to the 1,240 shares. Before that another transaction happened on Jan 06 ’25, when Company’s President & CEO sold 194,490 for $42.75, making the entire transaction worth $8,313,601. This insider now owns 2,366,570 shares in total.
Viking Therapeutics Inc (VKTX) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -86.48% per share during the next fiscal year.
Viking Therapeutics Inc (NASDAQ: VKTX) Trading Performance Indicators
Take a look at Viking Therapeutics Inc’s (VKTX) current performance indicators. Last quarter, stock had a quick ratio of 44.25.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.15, a number that is poised to hit -0.45 in the next quarter and is forecasted to reach -2.56 in one year’s time.
Technical Analysis of Viking Therapeutics Inc (VKTX)
Looking closely at Viking Therapeutics Inc (NASDAQ: VKTX), its last 5-days average volume was 3.18 million, which is a drop from its year-to-date volume of 4.45 million. As of the previous 9 days, the stock’s Stochastic %D was 47.92%. Additionally, its Average True Range was 1.97.
During the past 100 days, Viking Therapeutics Inc’s (VKTX) raw stochastic average was set at 29.13%, which indicates a significant decrease from 56.53% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 61.81% in the past 14 days, which was lower than the 84.10% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $26.50, while its 200-day Moving Average is $45.74. However, in the short run, Viking Therapeutics Inc’s stock first resistance to watch stands at $28.37. Second resistance stands at $29.19. The third major resistance level sits at $29.65. If the price goes on to break the first support level at $27.09, it is likely to go to the next support level at $26.63. Should the price break the second support level, the third support level stands at $25.81.
Viking Therapeutics Inc (NASDAQ: VKTX) Key Stats
The company with the Market Capitalisation of 3.09 billion has total of 112,310K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -109,960 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -45,630 K.
